<DOC>
	<DOC>NCT00189319</DOC>
	<brief_summary>The purpose of this study is to evaluate the management of paroxysmal atrial fibrillation with controlled release flecainide on patient's quality of life.</brief_summary>
	<brief_title>To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Flecainide</mesh_term>
	<criteria>In sinus rhythm at treatment initiation Experienced symptomatic AF episodes Left ventricular ejection fraction of at least 40% Females of child bearing potential must be using reliable method of contraception Intolerance and/or failure of previous therapy with flecainide immediate release Currently receiving &gt;200mg/day flecainide immediate release Severe symptoms during episodes of arrhythmia History of other cardiac conditions/abnormalities Heart surgery within the last 2 months Renal failure Pregnant or lactating females Significant extra cardiac or systemic disease Abnormal electrolyte levels Receiving defined cardiac and/or other treatments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Tambocor</keyword>
	<keyword>Paroxysmal Atrial Fibrillation</keyword>
	<keyword>Quality of Life</keyword>
</DOC>